Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

R. Edelson, C. Berger, F. Gasparro, B. Jegasothy, P. Heald, B. Wintroub, E. Vonderheid, R. Knobler, K. Wolff, G. Plewig

Research output: Contribution to journalArticle

Abstract

Systemically disseminated cutaneous T-cell lymphoma is generally resistant to chemotherapy and radiotherapy. We tested a treatment involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links DNA. After oral administration of methoxsalen, a lymphocyte-enriched blood fraction was exposed to ultraviolet A (1 to 2 J per square centimeter) and then returned to the patient. The combination of ultraviolet A and methoxsalen caused an 88 ± 5 percent loss of viability of target lymphocytes, whereas the drug alone was inactive. Twenty-seven of 37 patients with otherwise resistant cutaneous T-cell lymphoma responded to the treatment, with an average 64 percent decrease in cutaneous involvement after 22 ± 10 weeks (mean ± SD). The responding group included 8 of 10 patients with lymph-node involvement, 24 of 29 with exfoliative erythroderma, and 20 of 28 whose disease was resistant to standard chemotherapy. Side effects that often occur with standard chemotherapy, such as bone marrow suppression, gastrointestinal erosions, and hair loss, did not occur. Although the mechanism of the beneficial effect is uncertain, an immune reaction to the infused damaged cells may have restricted the activity of the abnormal T cells. This preliminary study suggests that extracorporeal photochemotherapy is a promising treatment for widespread cutaneous T-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)297-303
Number of pages7
JournalNew England Journal of Medicine
Volume316
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Photopheresis
Methoxsalen
Cutaneous T-Cell Lymphoma
Drug Therapy
Lymphocytes
Exfoliative Dermatitis
Alopecia
Oral Administration
Radiotherapy
Therapeutics
Lymph Nodes
Bone Marrow
T-Lymphocytes
Skin
DNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Edelson, R., Berger, C., Gasparro, F., Jegasothy, B., Heald, P., Wintroub, B., ... Plewig, G. (1987). Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New England Journal of Medicine, 316(6), 297-303.

Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. / Edelson, R.; Berger, C.; Gasparro, F.; Jegasothy, B.; Heald, P.; Wintroub, B.; Vonderheid, E.; Knobler, R.; Wolff, K.; Plewig, G.

In: New England Journal of Medicine, Vol. 316, No. 6, 1987, p. 297-303.

Research output: Contribution to journalArticle

Edelson, R, Berger, C, Gasparro, F, Jegasothy, B, Heald, P, Wintroub, B, Vonderheid, E, Knobler, R, Wolff, K & Plewig, G 1987, 'Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results', New England Journal of Medicine, vol. 316, no. 6, pp. 297-303.
Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New England Journal of Medicine. 1987;316(6):297-303.
Edelson, R. ; Berger, C. ; Gasparro, F. ; Jegasothy, B. ; Heald, P. ; Wintroub, B. ; Vonderheid, E. ; Knobler, R. ; Wolff, K. ; Plewig, G. / Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. In: New England Journal of Medicine. 1987 ; Vol. 316, No. 6. pp. 297-303.
@article{f366ee6381bb4c4085997476a81a7e02,
title = "Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results",
abstract = "Systemically disseminated cutaneous T-cell lymphoma is generally resistant to chemotherapy and radiotherapy. We tested a treatment involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links DNA. After oral administration of methoxsalen, a lymphocyte-enriched blood fraction was exposed to ultraviolet A (1 to 2 J per square centimeter) and then returned to the patient. The combination of ultraviolet A and methoxsalen caused an 88 ± 5 percent loss of viability of target lymphocytes, whereas the drug alone was inactive. Twenty-seven of 37 patients with otherwise resistant cutaneous T-cell lymphoma responded to the treatment, with an average 64 percent decrease in cutaneous involvement after 22 ± 10 weeks (mean ± SD). The responding group included 8 of 10 patients with lymph-node involvement, 24 of 29 with exfoliative erythroderma, and 20 of 28 whose disease was resistant to standard chemotherapy. Side effects that often occur with standard chemotherapy, such as bone marrow suppression, gastrointestinal erosions, and hair loss, did not occur. Although the mechanism of the beneficial effect is uncertain, an immune reaction to the infused damaged cells may have restricted the activity of the abnormal T cells. This preliminary study suggests that extracorporeal photochemotherapy is a promising treatment for widespread cutaneous T-cell lymphoma.",
author = "R. Edelson and C. Berger and F. Gasparro and B. Jegasothy and P. Heald and B. Wintroub and E. Vonderheid and R. Knobler and K. Wolff and G. Plewig",
year = "1987",
language = "English (US)",
volume = "316",
pages = "297--303",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "6",

}

TY - JOUR

T1 - Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results

AU - Edelson, R.

AU - Berger, C.

AU - Gasparro, F.

AU - Jegasothy, B.

AU - Heald, P.

AU - Wintroub, B.

AU - Vonderheid, E.

AU - Knobler, R.

AU - Wolff, K.

AU - Plewig, G.

PY - 1987

Y1 - 1987

N2 - Systemically disseminated cutaneous T-cell lymphoma is generally resistant to chemotherapy and radiotherapy. We tested a treatment involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links DNA. After oral administration of methoxsalen, a lymphocyte-enriched blood fraction was exposed to ultraviolet A (1 to 2 J per square centimeter) and then returned to the patient. The combination of ultraviolet A and methoxsalen caused an 88 ± 5 percent loss of viability of target lymphocytes, whereas the drug alone was inactive. Twenty-seven of 37 patients with otherwise resistant cutaneous T-cell lymphoma responded to the treatment, with an average 64 percent decrease in cutaneous involvement after 22 ± 10 weeks (mean ± SD). The responding group included 8 of 10 patients with lymph-node involvement, 24 of 29 with exfoliative erythroderma, and 20 of 28 whose disease was resistant to standard chemotherapy. Side effects that often occur with standard chemotherapy, such as bone marrow suppression, gastrointestinal erosions, and hair loss, did not occur. Although the mechanism of the beneficial effect is uncertain, an immune reaction to the infused damaged cells may have restricted the activity of the abnormal T cells. This preliminary study suggests that extracorporeal photochemotherapy is a promising treatment for widespread cutaneous T-cell lymphoma.

AB - Systemically disseminated cutaneous T-cell lymphoma is generally resistant to chemotherapy and radiotherapy. We tested a treatment involving the extracorporeal photoactivation of biologically inert methoxsalen (8-methoxypsoralen) by ultraviolet A energy to a form that covalently cross-links DNA. After oral administration of methoxsalen, a lymphocyte-enriched blood fraction was exposed to ultraviolet A (1 to 2 J per square centimeter) and then returned to the patient. The combination of ultraviolet A and methoxsalen caused an 88 ± 5 percent loss of viability of target lymphocytes, whereas the drug alone was inactive. Twenty-seven of 37 patients with otherwise resistant cutaneous T-cell lymphoma responded to the treatment, with an average 64 percent decrease in cutaneous involvement after 22 ± 10 weeks (mean ± SD). The responding group included 8 of 10 patients with lymph-node involvement, 24 of 29 with exfoliative erythroderma, and 20 of 28 whose disease was resistant to standard chemotherapy. Side effects that often occur with standard chemotherapy, such as bone marrow suppression, gastrointestinal erosions, and hair loss, did not occur. Although the mechanism of the beneficial effect is uncertain, an immune reaction to the infused damaged cells may have restricted the activity of the abnormal T cells. This preliminary study suggests that extracorporeal photochemotherapy is a promising treatment for widespread cutaneous T-cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=0023145057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023145057&partnerID=8YFLogxK

M3 - Article

C2 - 3543674

AN - SCOPUS:0023145057

VL - 316

SP - 297

EP - 303

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 6

ER -